Brief: Werewolf Therapeutics Highlights Safety And Efficacy Data From Its Ongoing Phase 1 Clinical Trial
25/06/2024 12:04
June 25 (Reuters) - Werewolf Therapeutics Inc HOWL.O :
* WEREWOLF THERAPEUTICS HIGHLIGHTS INITIAL SAFETY AND
EFFICACY
DATA FROM ITS ONGOING PHASE 1 CLINICAL TRIAL EVALUATING WTX-330
IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS OR
NON-HODGKIN LYMPHOMA
* WEREWOLF THERAPEUTICS: RESULTS SHOWED ENCOURAGING SIGNALS
OF
CLINICAL ACTIVITY
Source text for Eikon: ID:nGNX6jSy7t
Further company coverage: HOWL.O
((Reuters.Briefs@thomsonreuters.com;))